OctreoPharm Sciences Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$55.8M
OctreoPharm Sciences General Information
Description
Developer of radioactively labeled pharmaceuticals. The company is focused on the development of new radiopharmaceuticals for the detection, monitoring and treatment of neuroendocrine tumors.
Contact Information
Website
www.octreopharmsciences.comCorporate Office
- Biomedical Research Campus Berlin-Buch
- Robert-Roessle-Strasse 10, Building B55
- 13125 Berlin
- Germany
Corporate Office
- Biomedical Research Campus Berlin-Buch
- Robert-Roessle-Strasse 10, Building B55
- 13125 Berlin
- Germany
OctreoPharm Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 30-Jun-2015 | $55.8M | Completed | Generating Revenue | ||
| 2. Early Stage VC | 22-Jul-2013 | Completed | Startup | |||
| 1. Early Stage VC | 12-Apr-2011 | $7.09M | $7.09M | Completed | Startup |
OctreoPharm Sciences Comparisons
Industry
Financing
Details
OctreoPharm Sciences Competitors (3)
One of OctreoPharm Sciences’s 3 competitors is FluoroPharma, a Formerly VC-backed company based in Montclair, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| FluoroPharma | Formerly VC-backed | Montclair, NJ | ||||
| Navidea Biopharmaceuticals | Corporate Backed or Acquired | Columbus, OH | ||||
| Clarity Pharmaceuticals | Formerly VC-backed | Eveleigh, Australia |
OctreoPharm Sciences Patents
OctreoPharm Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11969484-B2 | Composition containing a somatostatin analogue for radiopharmaceutical use | Active | 21-Jun-2018 | ||
| US-20230181771-A1 | Composition containing a somatostatin analogue for radiopharmaceutical use | Active | 21-Jun-2018 | ||
| EP-3015462-A1 | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals | Inactive | 29-Oct-2014 | C07D255/02 |
OctreoPharm Sciences Signals
OctreoPharm Sciences Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eckert & Ziegler | Holding Company | Minority | ||
| Eckert Life Science Accelerator | Accelerator/Incubator | Minority | ||
| Eckert Wagniskapital und Frühphasenfinanzierung | Venture Capital | Minority | ||
| IBB Ventures | Venture Capital | Minority | ||
| KfW IPEX-Bank | Investment Bank | Minority |
OctreoPharm Sciences FAQs
-
When was OctreoPharm Sciences founded?
OctreoPharm Sciences was founded in 2009.
-
Where is OctreoPharm Sciences headquartered?
OctreoPharm Sciences is headquartered in Berlin, Germany.
-
What is the size of OctreoPharm Sciences?
OctreoPharm Sciences has 11 total employees.
-
What industry is OctreoPharm Sciences in?
OctreoPharm Sciences’s primary industry is Biotechnology.
-
Is OctreoPharm Sciences a private or public company?
OctreoPharm Sciences is a Private company.
-
What is the current valuation of OctreoPharm Sciences?
The current valuation of OctreoPharm Sciences is .
-
What is OctreoPharm Sciences’s current revenue?
The current revenue for OctreoPharm Sciences is .
-
How much funding has OctreoPharm Sciences raised over time?
OctreoPharm Sciences has raised $7.09M.
-
Who are OctreoPharm Sciences’s investors?
Eckert & Ziegler, Eckert Life Science Accelerator, Eckert Wagniskapital und Frühphasenfinanzierung, IBB Ventures, and KfW IPEX-Bank have invested in OctreoPharm Sciences.
-
Who are OctreoPharm Sciences’s competitors?
FluoroPharma, Navidea Biopharmaceuticals, and Clarity Pharmaceuticals are competitors of OctreoPharm Sciences.
-
When was OctreoPharm Sciences acquired?
OctreoPharm Sciences was acquired on 30-Jun-2015.
-
Who acquired OctreoPharm Sciences?
OctreoPharm Sciences was acquired by Ipsen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process